-
Mashup Score: 0Merck and EyeBio announce initiation of phase 2b/3 BRUNELLO trial evaluating MK-3000 for treatment of diabetic macular edema - 9 hour(s) ago
MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 0Boehringer Ingelheim to advance potential new treatment for geographic atrophy following positive Phase I results - 13 hour(s) ago
BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Boehringer Ingelheim and CDR-Life revealed positive results from the Phase I evaluation of BI 771716, an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). Read More: https://t.co/AwWM5tnubC
-
-
Mashup Score: 8Researchers detail acute angle closure glaucoma attack in patient with Hermansky-Pudlak syndrome - 17 hour(s) ago
In the case study, a 63-year-old patient presented with severe acute pain in the right eye, which was diagnosed as a pupillary block leading to acute angle closure glaucoma.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Researchers have conducted a study on the case of a patient with Hermansky-Pudlak syndrome who developed acute angle closure glaucoma following cataract surgery with anterior intraocular lens implantation Read More: https://t.co/3DEkHZez9M
-
-
Mashup Score: 0Lindus Health announces “All-in-One Ophthalmology CRO” - 21 hour(s) ago
The contract research organization and technology solution is for the execution of ophthalmology clinical trials.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Lindus Health announced its “All-in-One Ophthalmology CRO,” a contract research organization and technology solution for the execution of ophthalmology clinical trials. Read More: https://t.co/wbAMHGgaA4 https://t.co/yne9IT0VDH
-
-
Mashup Score: 0FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED - 1 day(s) ago
The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in 4Q calendar year 2024. Topline results currently are expected in late 2025
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Palatin Technologies Inc announced receipt of FDA correspondence confirming the acceptability of the protocols and endpoints for signs and symptoms of PL9643 Phase 3 pivotal clinical trials for dry eye disease (DED). Read More: https://t.co/1JoIb6s1Yr
-
-
Mashup Score: 1
The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Ocuphire Pharma announced it has dosed the first patient in its VEGA-3, phase 3 clinical trial (NCT06542497) of phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Read More: https://t.co/OTEbVy2sLy
-
-
Mashup Score: 0Lindus Health announces “All-in-One Ophthalmology CRO” - 2 day(s) ago
The contract research organization and technology solution is for the execution of ophthalmology clinical trials.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Lindus Health announced its “All-in-One Ophthalmology CRO,” a contract research organization and technology solution for the execution of ophthalmology clinical trials. Read More: https://t.co/wbAMHGgaA4 https://t.co/yne9IT0VDH
-
-
Mashup Score: 0Merck and EyeBio announce initiation of phase 2b/3 BRUNELLO trial evaluating MK-3000 for treatment of diabetic macular edema - 2 day(s) ago
MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Merck and EyeBio have announced the initiation of the phase 2b/3 BRUNELLO trial (NCT06571045) evaluating MK-3000 (Restoret, formerly EYE103) for the treatment of diabetic macular edema (DME). Read More: https://t.co/0Mi42irL8H
-
-
Mashup Score: 8Researchers detail acute angle closure glaucoma attack in patient with Hermansky-Pudlak syndrome - 2 day(s) ago
In the case study, a 63-year-old patient presented with severe acute pain in the right eye, which was diagnosed as a pupillary block leading to acute angle closure glaucoma.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Researchers have conducted a study on the case of a patient with Hermansky-Pudlak syndrome who developed acute angle closure glaucoma following cataract surgery with anterior intraocular lens implantation Read More: https://t.co/3DEkHZez9M
-
-
Mashup Score: 0Boehringer Ingelheim to advance potential new treatment for geographic atrophy following positive Phase I results - 2 day(s) ago
BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet-
Boehringer Ingelheim and CDR-Life revealed positive results from the Phase I evaluation of BI 771716, an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). Read More: https://t.co/AwWM5tnubC
-
Merck and EyeBio have announced the initiation of the phase 2b/3 BRUNELLO trial (NCT06571045) evaluating MK-3000 (Restoret, formerly EYE103) for the treatment of diabetic macular edema (DME). Read More: https://t.co/0Mi42irL8H